TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Percent of current diagnosed hypertensive patients with BP <140/90 (or BP<130/80 for patients with diabetes) at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percent of patients with HbA1c <7 (for patients with hypertension + diabetes) at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: CFTR-mediated Total Chloride Transport
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in concentration of allergen specific Immunoglobin E antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: AUC0-∞ of BI 671800 in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Administered dose of propofol for induction of anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained Virologic Response After 12 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antioxidant profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alcohol Craving in Response to the Alcohol Cue Script
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alcohol Craving in Response to the Lipopolysaccharide Challenge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alcohol Craving in Response to the Stress Script
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Event rate of MyPreOp assessments affecting perioperative management
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Pesticide Self-poisoning
Endpoint domain: Mortality/survival
Primary endpoint: Stroke length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average swing speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lateral velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in circulating endothelial cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety of ceftaroline fosamil
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction or elimination of myopia and myopic astigmatism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of headache
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Altered quantitative metagenomics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes of Levator Hiatal Area During Valsava
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Pelvic Floor Muscle Contraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of Alemtuzumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Indirect language comprehension
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Proportion of illicit opioid-negative urine samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects with negative results
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Change From Baseline in HAQ-DI Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in DAS28-CRP From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum ketone bodies level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum chemerin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: AUC of BG00012
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of BG00012
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activity of preparative regimen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HBsAg loss or appearance of anti-HBs antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Area under the curve (AUC) viral load of RSV-A Memphis 37b
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Daily dose needed to reach the targeted plasma level of everolimus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to reach the targeted plasma level of everolimus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute uptake of [18F]dabrafenib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gambling Symptom Assessment Scale (G-SAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of Gambling Problems and Services Need
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Canadian Problem Gambling Index (CPGI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratio of participants screened to patients completing 12-week measures
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Average score of adapted INSHAPE computer-based questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Area Under the Curve of Receiver Operating Characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: An optimal cut-off threshold of Anion Gap
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motor Function Measure 32 (MFM32)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in symptom burden as measured by EPIC-S
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in HRQoL as measured by the FACT questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in HRQoL as measured by the PROMIS Fatigue questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in HRQoL as measured by the PROMIS Pain questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Maximum observed concentration (Cmax) of Tenofovir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve (AUCt) of Tenofovir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduced operative time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduced C-arm exposure
Endpoint domain: Adverse events/effects
Primary endpoint: Reduces inadvertent nail misses
Endpoint domain: Adverse events/effects
Primary endpoint: No complications
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Postvaccination Varicella Antibody Titer ≥ 5 gpELISA Units/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With Postvaccination Measles Antibody Titer ≥ 120 mIU/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With Postvaccination Mumps Antibody Titer ≥ 10 Ab Units/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With Postvaccination Rubella Antibody Titer ≥ 10 IU/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: brain sodium ion homeostasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for surfactant
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Sustained Virologic Response 12 Weeks Post-treatment (SVR12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from baseline insulin sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Patient's perception of symptom variability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cardiovascular Medication Changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Health Care Utilizations
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Specific Immunoglobulin E (IgE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Nasal Symptom Scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Quality of Life Measure
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Area under the concentration-time curve (AUROCCs) for MR-proADM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve (AUROCCs) for the CT-proET-1/MR-proADM-ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to reach maximum (peak) plasma concentration (tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With High Grade Treatment Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Daily time in Off
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Sputum Viscosity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean Expectoration Difficulty Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: severe late toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Forced Expiratory Volume at One Second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Structural Injury Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: gene expression profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: endometrium phase assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of tumor sizes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Admission alive to hospital
Endpoint domain: Mortality/survival
Primary endpoint: Change in MCCB Neurocognitive Composite Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants With Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Clinically Significant Differences in C-SSRS Values
Endpoint domain: Adverse events/effects
Primary endpoint: BMI Percentile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reading speed for 1.3M print
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma BHB elevation time course of GSK2981710
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the time concentration curve (AUC) of GSK2981710
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum concentration (Cmax) of GSK2981710
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in performance on CANTAB Paired Associates Learning task
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change from Baseline in performance on CANTAB Verbal Recognition Memory task
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: 30-day Composite Major Adverse Cardiac Event (MACE)
Endpoint domain: Adverse events/effects
Primary endpoint: 12-month Composite Major Adverse Cardiac Event (MACE)
Endpoint domain: Adverse events/effects
Primary endpoint: Collection of blood samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Completion of FFQ's and/or diet recall questionnaires
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cardiovascular Ultrasound scans (USS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Tissue elasticity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global Neurocognitive Function
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: reduced fluid accumulation in the pleural cavity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proliferative retinopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Quantitative clinical evaluation of Actinic keratoses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Qualitative clinical evaluation of Actinic keratoses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Qualitative evaluation of global clinical skin change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Patellofemoral cartilage changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Cannabis Abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Type 2 Diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Subjective units of distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Fear Related Psychological Concerns (Falls)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Fear Related Psychological Concerns (Balance)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Fear Related Psychological Concerns (Fear)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: maximal tolerated dose (MTD) of capecitabine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gingival Crevicular fluid volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in blood pressure averages
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Dyspnea assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of early postoperative cognitive dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Menstrual pain (dysmenorrhea)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in treatment strategy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Dermatology Life Quality Index (DLQI) improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Regression of coronary artery lesion (CAL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Quantity of Recurrent Episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Change in antibody titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of subjects reporting infusion related reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects that develop changes in detectable antidrug antibodies to MEDI9090
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cancer survivorship experience
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mental status of cancer survivors
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Drug use at 3 months
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Drug use at 6 months
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Completion rate of education sessions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Pain Interference
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Discontinuation due to adverse events or other reasons
Endpoint domain: Adverse events/effects
Primary endpoint: PrEP uptake
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Protein overexpression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentages of Non-pregnant Subjects With Antibody Concentrations Above a Defined Threshold at One Month After the Second Vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Antibody Geometric Mean Concentrations (GMC) in Non-pregnant Women at One Month After the Second Vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentages of Maternal Subjects With Antibody Concentrations Above a Defined Threshold at Day of Delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Antibody GMC in Maternal Subjects at Day of Delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence rate of dose-limiting toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Shoulder Pain (NPRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Shoulder Pain and Disability Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: 12-month Primary Patency Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: 12-month Limb Salvage Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incidence and severity of treatment-emergent adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Oral Health Related Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: (PCr)-to-ATP ratio levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: failure rate of catheterization
Endpoint domain: Adverse events/effects
Primary endpoint: Simulated driving performance (SDLP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acid rebound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Implant Stability Scale (ISQ) Score Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transfusion of 6 or more units of packed Red Blood Cells (RBC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: CT Abdomen results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infarct/haemorrhage size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients Demonstrating Somatostatin Receptor Positivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: improvement of tissue oxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sitting SBP change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in the intensity of pain in the neck or/and low back
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: uAQP2 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: exploratory pharmacodynamic markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Probability of death/reoperation
Endpoint domain: Mortality/survival
Primary endpoint: Probability of Major Adverse Cardiac and Cerebro-vascular Event (MACCE)
Endpoint domain: Mortality/survival
Primary endpoint: Success rate of valve placement and implantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Crime
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Cmax of Total Iron
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain oxygen levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Symptom distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Symptom impact
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: numbers of CD1c and CD141 cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: relative change in average daily Epistaxis VAS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of at least 20% over placebo of numerical Pain Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of at least 20% over placebo with the R-DS scale (Rasch-built Overall Disability Scale)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Relative Cerebral Blood Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Relative Cerebral Blood Flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Vessel Diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Cardiac status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Muscle tissue quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes